Brief: Biohaven Provides Update On Taldefgrobep Alfa Development Program
25/11/2024 12:43
Nov 25 (Reuters) - Biohaven Ltd BHVN.N :
* BIOHAVEN PROVIDES UPDATE ON TALDEFGROBEP ALFA DEVELOPMENT
PROGRAM FOR SPINAL MUSCULAR ATROPHY AND OBESITY
* BIOHAVEN LTD - TALDEFGROBEP WELL-TOLERATED WITH NO
TREATMENT-RELATED SAES
Source text: ID:nPn9s2wWza
Further company coverage: BHVN.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing